Therapeutic potential of CDK inhibitors in MLL leukemias

被引：1
|
作者：
Frame, Sheelagh
Hogben, Morag
Munro, Clare
Blake, David G.
Green, Simon R.
Zheleva, Danielle I.
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-3886
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3886
引用
收藏
页数：3
相关论文
共 50 条
  • [21] The MLL recombinome of acute leukemias in 2013
    C Meyer
    J Hofmann
    T Burmeister
    D Gröger
    T S Park
    M Emerenciano
    M Pombo de Oliveira
    A Renneville
    P Villarese
    E Macintyre
    H Cavé
    E Clappier
    K Mass-Malo
    J Zuna
    J Trka
    E De Braekeleer
    M De Braekeleer
    S H Oh
    G Tsaur
    L Fechina
    V H J van der Velden
    J J M van Dongen
    E Delabesse
    R Binato
    M L M Silva
    A Kustanovich
    O Aleinikova
    M H Harris
    T Lund-Aho
    V Juvonen
    O Heidenreich
    J Vormoor
    W W L Choi
    M Jarosova
    A Kolenova
    C Bueno
    P Menendez
    S Wehner
    C Eckert
    P Talmant
    S Tondeur
    E Lippert
    E Launay
    C Henry
    P Ballerini
    H Lapillone
    M B Callanan
    J M Cayuela
    C Herbaux
    G Cazzaniga
    Leukemia, 2013, 27 : 2165 - 2176
  • [22] The MLL recombinome of acute leukemias in 2013
    Meyer, C.
    Hofmann, J.
    Burmeister, T.
    Groeger, D.
    Park, T. S.
    Emerenciano, M.
    de Oliveira, M. Pombo
    Renneville, A.
    Villarese, P.
    Macintyre, E.
    Cave, H.
    Clappier, E.
    Mass-Malo, K.
    Zuna, J.
    Trka, J.
    De Braekeleer, E.
    De Braekeleer, M.
    Oh, S. H.
    Tsaur, G.
    Fechina, L.
    van der Velden, V. H. J.
    van Dongen, J. J. M.
    Delabesse, E.
    Binato, R.
    Silva, M. L. M.
    Kustanovich, A.
    Aleinikova, O.
    Harris, M. H.
    Lund-Aho, T.
    Juvonen, V.
    Heidenreich, O.
    Vormoor, J.
    Choi, W. W. L.
    Jarosova, M.
    Kolenova, A.
    Bueno, C.
    Menendez, P.
    Wehner, S.
    Eckert, C.
    Talmant, P.
    Tondeur, S.
    Lippert, E.
    Launay, E.
    Henry, C.
    Ballerini, P.
    Lapillone, H.
    Callanan, M. B.
    Cayuela, J. M.
    Herbaux, C.
    Cazzaniga, G.
    LEUKEMIA, 2013, 27 (11) : 2165 - 2176
  • [23] CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
    Saleh, Lubaid
    Wilson, Caroline
    Holen, Ingunn
    MEDCOMM, 2021, 2 (04): : 514 - 530
  • [24] The MLL recombinome of acute leukemias in 2017
    Meyer, C.
    Burmeister, T.
    Groeger, D.
    Tsaur, G.
    Fechina, L.
    Renneville, A.
    Sutton, R.
    Venn, N. C.
    Emerenciano, M.
    Pombo-de-Oliveira, M. S.
    Blunck, C. Barbieri
    Lopes, B. Almeida
    Zuna, J.
    Trka, J.
    Ballerini, P.
    Lapillonne, H.
    De Braekeleer, M.
    Cazzaniga, G.
    Abascal, L. Corral
    van der Velden, V. H. J.
    Delabesse, E.
    Park, T. S.
    Oh, S. H.
    Silva, M. L. M.
    Lund-Aho, T.
    Juvonen, V.
    Moore, A. S.
    Heidenreich, O.
    Vormoor, J.
    Zerkalenkova, E.
    Olshanskaya, Y.
    Bueno, C.
    Menendez, P.
    Teigler-Schlegel, A.
    zur Stadt, U.
    Lentes, J.
    Goehring, G.
    Kustanovich, A.
    Aleinikova, O.
    Schafer, B. W.
    Kubetzko, S.
    Madsen, H. O.
    Gruhn, B.
    Duarte, X.
    Gameiro, P.
    Lippert, E.
    Bidet, A.
    Cayuela, J. M.
    Clappier, E.
    Alonso, C. N.
    LEUKEMIA, 2018, 32 (02) : 273 - 284
  • [25] The MLL recombinome of acute leukemias in 2017
    C Meyer
    T Burmeister
    D Gröger
    G Tsaur
    L Fechina
    A Renneville
    R Sutton
    N C Venn
    M Emerenciano
    M S Pombo-de-Oliveira
    C Barbieri Blunck
    B Almeida Lopes
    J Zuna
    J Trka
    P Ballerini
    H Lapillonne
    M De Braekeleer
    G Cazzaniga
    L Corral Abascal
    V H J van der Velden
    E Delabesse
    T S Park
    S H Oh
    M L M Silva
    T Lund-Aho
    V Juvonen
    A S Moore
    O Heidenreich
    J Vormoor
    E Zerkalenkova
    Y Olshanskaya
    C Bueno
    P Menendez
    A Teigler-Schlegel
    U zur Stadt
    J Lentes
    G Göhring
    A Kustanovich
    O Aleinikova
    B W Schäfer
    S Kubetzko
    H O Madsen
    B Gruhn
    X Duarte
    P Gameiro
    E Lippert
    A Bidet
    J M Cayuela
    E Clappier
    C N Alonso
    Leukemia, 2018, 32 : 273 - 284
  • [26] The Therapeutic Potential of CDK4/6 Inhibitors, Novel Cancer Drugs, in Kidney Diseases
    Liang, Xuan-Bing
    Dai, Zhi-Cheng
    Zou, Rong
    Tang, Ji-Xin
    Yao, Cui-Wei
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)
  • [27] Tyrosine kinases in KMT2A/MLL-rearranged acute leukemias as potential therapeutic targets to overcome cancer drug resistance
    Uckun, Fatih M.
    Qazi, Sanjive
    CANCER DRUG RESISTANCE, 2022, 5 (04) : 902 - 916
  • [28] Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias through MLL-AF4
    Liu, Han
    Westergard, Todd D.
    Cashen, Amanda
    Piwnica-Worms, David R.
    Kunkle, Lori
    Vij, Ravi
    Pham, Can G.
    DiPersio, John
    Cheng, Emily H.
    Hsieh, James J.
    CANCER CELL, 2014, 25 (04) : 530 - 542
  • [29] Structure-guided design of inhibitors of the menin-mixed lineage leukemia (MLL) interaction for the treatment of MLL-associated leukemias
    Senter, Timothy J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [30] Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer
    Goel, Bharat
    Tripathi, Nancy
    Bhardwaj, Nivedita
    Jain, Shreyans K.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2020, 20 (17) : 1535 - 1563
12345